论文部分内容阅读
目的 研究小活络丸对小鼠再次免疫应答、特异性免疫、非特异性免疫和自由基损伤,以及对疼痛及多种急性渗出性炎症模型、琼脂肉芽组织增殖性炎症模型的药理作用。方法 以两次腹膜内注射鸡红细胞(CRBC)诱导免疫增强病理模型探讨再次免疫应答;以2,4-二硝基氟苯(DNFB)诱导由1型T辅助性细胞以及巨噬细胞和B细胞联合介导的迟发型超敏反应(DTH)模型探讨细胞免疫;以碳粒廓清试验探讨MPS功能;以红细胞免疫粘附作用探讨红细胞免疫功能;以CRBC诱导小鼠病理模型的特异性抗体IgM溶血素活性(HC_(50)值)、丙二醛(MDA)含量和超氧化物歧化酶(SOD)活性评价特异性体液免疫功能和抗自由基损伤能力;以及二甲苯、巴豆油和角叉菜胶致急性渗出性炎症模型、琼脂肉芽组织增殖性炎症模型及醋酸性疼痛模型;验证小活络丸的药效学效应。结果 小活络丸能降低再次免疫应答中高值的IgG和循环免疫复合物(CIC)含量和提高低下的C_3水平(P<0.05～0.01);抑制DTH、MPS的吞噬功能和红细胞免疫粘附功能(P<0.01);抑制CRBC诱导小鼠特异性抗体IgM型溶血素活性(P<0.01),提高C_3水平(P<0.01),降低MDA含量(P<0.01),对SOD活性则未见显著改变(P>0.05);并显示抗增殖性炎症、镇痛等的药理作用(P<0.05～0.01);短疗程给药,则未见抑制急性渗出性炎症水肿反应(P>
Objective To study the re-immune response, specific immunity, non-specific immunity and free radical damage of Xiao Huo Luo Pill on mice, as well as the pharmacological effects on pain, multiple models of acute exudative inflammation, and proliferative inflammation model of agar granulation tissue. Methods Two-peritoneal injection of chicken erythrocytes (CRBC) induced immune enhancement pathological model to explore the re-immune response; 2,4-dinitrofluorobenzene (DNFB) induced by type 1 T helper cells and macrophages and B cells Combined cell-mediated immunity with delayed-type hypersensitivity (DTH) model; MPS function with carbon particle clearance test; Erythrocyte immune function with red blood cell immune adhesion; Specific antibody IgM hemolysis induced by CRBC in mouse pathological model Sustaining activity (HC 50 ), malondialdehyde (MDA) content and superoxide dismutase (SOD) activity evaluate specific humoral immune functions and resistance to free radical damage; and xylene, croton oil and carrageenan Gel-induced acute exudative inflammation model, agar granulation tissue proliferative inflammation model and acetic acid pain model; verify the pharmacodynamic effect of Xiao Huo Luo Wan. Results Xiaohuoluo pill can reduce the high value of IgG and circulating immune complex (CIC) content in the re-immune response and increase the low C3 level (P<0.05-0.01); inhibit the phagocytic function of DTH, MPS, and red blood cell immune adhesion function ( P<0.01); inhibition of CRBC-induced mouse specific antibody IgM-type hemolysin activity (P <0.01), increased C3 level (P <0.01), reduced MDA content (P <0.01), no significant change in SOD activity (P>0.05); The pharmacological effects of anti-proliferative inflammation, analgesia, etc. were shown (P<0.05-0.01); in the short course of administration, no acute exudative inflammatory edema reaction was seen (P>